TrialCornea2015

Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab.

Cynthia L Grosskreutz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.